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Mo~oclonaI ntibodies (QBOI and 1200) prepared against hums prolactin (hPRL) have helped efine a 
variant form of the hormone. This variant is of apparently higher molecular mass (26 kDa) than the 
predominant form of the hormone (24 kDa) and its presence does not appear to be species-restricted. The
demonstration f the 26 kDa form of hPRL in fresh pituitary tissue and amniotic fluid suggests it may 
retain some specific function. 
Pro~act~n Variant Fragment ~onoelona~ antibody SDS-PA GE rmmanoblotting 
1. INTRODUCTION 
Human prolactin (hPRL) is a single chain pro- 
tein which shares extensive sequence homology 
(60-80%) with prolactins from other species [I]. 
Although it is phylogenetically related to both 
human growth hormone (hGH) and human 
chorionic somatomammotrophin (hCS), it retains 
only limited (1Wo) structural homology with these 
two hormones [2,3]. In addition to structural 
overlap, all 3 hormones display both lactogenic 
and somatotropic activities to varying degrees [4]. 
Growth hormone has been demonstrated to exist 
in a number of forms which include both structural 
variants derived from alternative processing of 
mRNA precursors [S] (20 kDa form), as well as 
variants which are believed to arise from post- 
translational modification of the intact molecule 
by proteases [6]. In the case of the former, it ap- 
pears that alternative splicing of hGH nuclear 
RNA precursors results in a deletion of a linear se- 
quence of 15 amino acids near the NH*-terminal 
Abbreviations: hPRL, human prolactin; hGH, human 
growth hormone; hCS, human chorionic somatomam- 
motrophin; MAB, monoclonal antibody 
end of the molecule. Proteolytic modification 
hGH results in cleavage in the sequence region 
134-146 [6] and gives rise to a ‘two-chain’ form 
composed of two polypeptides of 15 kDa and 
7 kDa, respectively. 
In addition to the predominant, 24 kDa form of 
prolactin [7,8], we have here identified a higher 
variant (26 kDa) as well as several fragments (18, 
16 and 8 kDa) of the hormone with the aid of 
monoclonal antibodies (IvIAB). The 26 kDa form 
has been shown to be present also in purified 
bovine and ovine prolactin preparations as well as 
in crude human pituitary extracts and amniotic 
fluid. However, highly purified pituitary hPRL 
contained only the single species of monomeric 
hormone corresponding to 24 kDa. The demon- 
stration of the 26 kDa variant form of hPRL in a 
number of ‘native’ preparations of the hormone is 
consistent with its possible physiological origin. 
2. METHODS 
2.1. Preparation of hormones 
Human prolactin was affinity purified from the 
hPRL-rich side fractions derived during the 
192 
Published by EIsevier Science Publishers B. V. 
00145793/84/$3.00  1984 Federation of European Biochemical Societies 
Volume 171, number 2 FEBS LETTERS June 1984 
purification of hGH from pituitary glands, based 
upon the method in [9] and obtained from the 
Public Health Lab. Service (Porton Down). This 
material was homogenised in sodium bicarbonate 
buffer (pH 8.3, 0.05 M) in the presence of 
phenylmethylsulphonyl f uoride (2 mM, PMSF) at 
4°C prior to two consecutive centrifugations of 
1000 x g and 20000 x g in order to remove insolu- 
ble material. The supernatant was applied to an af- 
finity column (20 X 1.2 cm) containing 100 mg 
monoclonal antibody (QBOl) [lo] immobilized on 
CNBr-activated Sepharose (Pharmacia). Retained 
material was washed extensively with phosphate- 
buffered saline (PBS) prior to elution with sodium 
iodide (2.5 mM) and dialysis against PBS. Highly 
purified hPRL was a gift from Dr P.J. Lowry (St. 
Bartholomews Hospital, London) whereas bovine 
PRL (bPRL) and ovine PRL (oPRL) were ob- 
tained from Dr M. Wallis (University of Sussex, 
Brighton). hGH was prepared as in [I I] from in- 
dividual human, cadaveric pituitary glands and 
stored frozen at -70°C. Thawed glands were 
homogenized in sodium bicarbonate buffer as 
above and solubilized in SDS-containing buffer 
[Tris-HCl, 100 mM (pH 6.8) containing SDS, 5% 
(w/v), dithiothreitol, DTT 100 mM and glycerol 
10% (v/v)]. Similarly, human amniotic fluid, ob- 
tained freshly post-partum and stored at -2O”C, 
was directly treated by boiling in SDS-buffer for 
5 min. 
trophoretic transfer of proteins from SDS-gels to 
nitrocellulose sheets [16] was performed in Tris- 
glycine buffer (Tris 25 mM, glycine 20 mM, pH 
8.2, containing 20%, v/v, methanol) for 2 h at 
20°C. The nitrocellulose paper was subsequently 
immersed into 5% (w/v) bovine haemoglobin, 
0.01% NaN3 in PBS in order to block free binding 
sites on the paper. Radioiodinated antibody 
([1251]1200) was then added (20000 cpm/ml) to the 
nitrocellulose strips and shaken for 2 h at 22°C. 
This was followed by 3 consecutive washes with 
PBS (20 min/wash). Bands were visualized by 
autoradiography of the dried nitrocellulose sheets 
and molecular masses were determined from 
standard protein markers (BDH). 
3. RESULTS 
2.2. Monoclonal antibodies 
The antibodies derived from murine hybridoma 
cell lines have been prepared by standard tech- 
niques [ 121. Antibody QBOl was highly specific for 
hPRL [lo] and failed to cross-react with either 
hGH, hCS or with ovine and bovine prolactins. 
However, antibody 1200 [13] cross-reacted with 
ovine and bovine prolactins in addition to hPRL, 
as demonstrated here. Radioiodination of 1200 
globulin (50/g) was performed by the ‘iodogen’ 
method as in [14]. 
2.3. SDS-PAGE and immunoblotting 
Examination of antibody QBOl affinity purified 
hPRL, by SDS-PAGE and immunoblotting with 
[1251]1200 antibody, revealed the presence of two 
monomeric forms of the hormone with apparent 
molecular masses of 24 and 26 kDa, respectively 
(fig.lA, lanes 1,2). Dimeric prolactin was present 
in some preparations (lane 3) in much smaller 
quantities than the monomeric forms. Bands cor- 
responding to fragments of hPRL were found 
despite the precaution of performing all steps at 
4°C in the presence of PMSF. In the prolactin 
preparations hown in lanes 1 and 2, the fragments 
consistently ran with higher mobilities than the 
fragments for the preparation shown in lane 3. 
This difference probably arises from inadequate 
reduction of enzymatic activity in the tissue 
homogenates by the presence of PMSF and low 
temperature. Although the intensity and mobilities 
of these fragments were somewhat variable, three 
distinct bands corresponding to 18, 16 and 8 kDa, 
respectively, were discernable (lane 3). Such a band 
profile is consistent with the presence of two 
monomeric variant forms of hPRL (26 and 
24 kDa), with the structural difference residing 
within only one fragment. 
Polyacrylamide gel electrophoresis (PAGE) was Binding of [‘*‘I] 1200 antibody to either hGH or 
performed as in [15] in the presence of SDS under hCS (fig. lA, lanes 4,5) was not observed, although 
reducing conditions. Solubilized proteins were the relative mobility of hGH to the prolactin bands 
applied to slab gels consisting of a 5% acrylamide is shown in lane 6. However, the only monomeric 
stacking gel and a 15% running gel and sub- species of hPRL in preparations which had been 
sequently submitted for immunoblotting. The elec- highly purified by protein fractionation techniques 
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Fig. 1. SDS-PAGE-immunoblot profile of prolactins 
developed with ‘Z51-labelled 1200 monoclonal antibody. 
(A) Lanes l-3, different preparations of prolactin which 
have been affinity purified from human pituitary 
homogenate by monoclonal antibody QBOI (5 gg/lane); 
lane 4, hCH (10ag); lane 5, hCS (1Opg); lane 6, 
[“sI]hGH; lane 7, hPRL highly purified by protein 
fractionation techniques [7] (1Opg). (B) Lane 8, SDS- 
solubilized human pituitary homogenate; lane 9, 
amniotic fluid 20 1; lane 10, bovine prolactin (10 fig); 
lane 11, ovine prolactin (10 pg); lane 12, SDS-solubilized 
rat pituitary homogenate. 
[7] instead of by affinity chromatography, cor- 
responded to the 24 kDa form (lane 7). Elec- 
trophoretic separation and immunoblotting of 
SDS solubilized preparations of human pituitary 
gland or of human amniotic fluid indicated that 
the 26 kDa variant was also present (fig.lB, lane 8 
and 9, respectively). Fragments of hPRL were only 
identified in amniotic fluid preparations uggesting 
they may be ‘normally’ processed constituents of 
this fluid. The binding of [*251]1200 antibody to a 
number of different fragments in affinity purified 
preparations derived from both pituitary glands 
and solubilized amniotic fluid indicates that the 
corresponding determinant may be repeated within 
the hormone’s antigenic structure. An analogous 
situation exists for hGH, where it has recently been 
shown that one MAB can bind to two structurally 
non-overlapping fragments [ 171. 
The cross-reactivity of [‘251]1200 with non- 
primate prolactins permitted the examination of 3 
preparations for the presence of the 26 kDa 
variant form. Preparations of both bPRL (lane 10) 
and oPRL (lane 11) gave demonstrable quantities 
of the 26 kDa band; however, this was substantial- 
ly reduced in the case of bPRL. Furthermore, 
preparations of rat pituitary glands which had 
been solubilized in SDS-buffer resulted in no bind- 
ing, suggesting that this determinant is species- 
restricted (lane 12). Fragments of prolactin were 
furthermore observed in bPRL and oPRL prepara- 
tions in addition to significant amounts of material 
of slower mobility (45-52 kDa). 
4. DISCUSSION 
Two monoclonal antibodies, one specific for 
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hPRL (QBOl) and one also cross-reacting with cer- 
tain non-primate prolactins (1200) have enabled 
the identification of a 26 kDa variant form of the 
hormone. Its demonstration in both pituitary 
gland and amniotic fluid preparations indicates 
that it is physiologic~ly produced. It is highly 
unlikely that the 26 kDa variant is a prolactin- 
related protein with partial structural homology 
since the two antibodies employed bind to distinct 
determinants within the hormone structure. Fur- 
thermore, neither hGH or hCS cross-reacted with 
either of these monoclon~ antib~ies despite the 
phylogenic homology which exists between these 
hormones and prolactin. The major form of pro- 
lactin described exhibits an apparent molecular 
mass of 24 kDa on SDS-PAGE and represents the 
only identifiable monomeric species in prepara- 
tions of the hormone derived by protein fractiona- 
tion techniques [7,18}. This result suggests that the 
26 and 24 kDa forms differ significantly in 
physical or chemical characteristics. 
Several fragments of PRL have been observed, 
in addition to the 26 kDa variant in affinity 
purified preparations of the pituita~ hormone and 
in amniotic fluid. Their variation in elec- 
trophoretic mobility and their absence from 
preparations of SDS-solubilized fresh pituitary 
tissue suggests that they may result from non- 
specific cleavage by proteases. However, some of 
these fragments (fig.lA, lane 3) displayed 
molecular mass profiles consistent with them being 
derived from two monomeric species differing in 
structure at either the N- or C-terminal ends of the 
molecule. An analogous system has been 
demonstrated with a genetic variant of hGH which 
retains a molecular mass of 20 instead of 22 kDa 
and results from a I5 amino acid deletion in the se- 
quence of the latter form. Studies [19] have in- 
dicated that proteolytically cleaved forms of rat 
prolactin are biologically active and retain proper- 
ties distinct from the parent molecule. Indeed, ex- 
tensive studies with cleaved forms of hGH have 
shown that such modified forms have amplified 
biological activities [20], 
Molecular heterogeneity of PRL preparations 
has been noted in [21] during the separation of 
‘isohormones’ on a charge basis. However, these 
forms were apparently indistinguishable on the 
basis of molecular mass and were separated on 
polyacrylamide gels under non-denaturing condi- 
tions. Furthermore, multiple immunoa~ive com- 
ponents of ‘large’ forms of hPRL (40-50 kDa) 
have been identified in the plasma of patients with 
pituitary tumours [22]. However, authors in [23] 
have demonstrated that extraction of prolactin at 
acid pH can lead to pol~e~zation of the hor- 
mone. Identification of high forms (40-50 kDa) of 
hPRL in purified or processed preparations of the 
hormone but not in pituitary or amniotic fluid 
raises the possibility that they are artifactual. The 
consistent demonstration of the 26 kDa variant 
form of prolactin in affinity purified hormone, 
pituitary and amniotic fluid preparations and some 
non-primate preparations of the hormone favours 
the view that it is physiologically produced. 
Although the underlying structural differences 
which result in the slower mobility of the 26 kDa 
form have not been established, it is conceivable 
that they stem from differences in amino acid se- 
quence. Furthermore, the complete absence of the 
26 kDa form from highly purified prolactin 
preparations indicates that it retains significant 
physiochemical differences from the major 
molecular species (24 kDa). Structure variation in 
prolactin molecules may have arisen from genetic 
polymorphism within a population. However, this 
seems unlikely since pituitaries obtained from at 
least 8 individuals were examined and demonstrat- 
ed to contain both the 24 and 26 kDa variant 
forms of the hormone. 
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